Phase II Study Comparing 3 vs 4 Sessions of Brachytherapy for Cervical Cancer
Sponsor: Stanford University
Sponsor score: 40
ClinicalTrials ID:NCT07022470
This clinical trial is exploring whether using 3 sessions of high-dose brachytherapy is as effective and feasible as the standard 4 sessions for treating locally advanced cervical cancer.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The study aims to determine if 3 sessions of high-dose brachytherapy can be a viable alternative to the standard 4 sessions for patients with locally advanced cervical cancer. Brachytherapy is a type of internal radiation treatment that targets cancer cells in the cervix.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with cervical cancer and scheduled to receive brachytherapy as part of the main treatment.
- In good general health, with an ECOG performance status between 0 and 2, meaning fully active or able to carry out light work.
- Aged 18 years or older.
- Able to understand the study details and willing to sign a written consent form.
Exclusion Criteria
- Unable to receive radiotherapy as determined by the radiation doctor.
- Unable to have an MRI scan.
- Have had radiation treatment to the pelvic area more than 3 months ago.
- Under 18 years old.
- Pregnant or breastfeeding.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Stanford University | 94304 | Palo Alto | California |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.